Search Results - "Roth, Jennifer A"

Massively parallel pooled screening reveals genomic determinants of nanoparticle delivery by Boehnke, Natalie, Straehla, Joelle P, Safford, Hannah C, Kocak, Mustafa, Rees, Matthew G, Ronan, Melissa, Rosenberg, Danny, Adelmann, Charles H, Chivukula, Raghu R, Nabar, Namita, Berger, Adam G, Lamson, Nicholas G, Cheah, Jaime H, Li, Hojun, Roth, Jennifer A, Koehler, Angela N, Hammond, Paula T

“…To accelerate the translation of cancer nanomedicine, we used an integrated genomic approach to improve our understanding of the cellular processes that govern…”
Get full text

Multiplexed single-cell transcriptional response profiling to define cancer vulnerabilities and therapeutic mechanism of action by McFarland, James M., Paolella, Brenton R., Warren, Allison, Geiger-Schuller, Kathryn, Shibue, Tsukasa, Rothberg, Michael, Kuksenko, Olena, Colgan, William N., Jones, Andrew, Chambers, Emily, Dionne, Danielle, Bender, Samantha, Wolpin, Brian M., Ghandi, Mahmoud, Tirosh, Itay, Rozenblatt-Rosen, Orit, Roth, Jennifer A., Golub, Todd R., Regev, Aviv, Aguirre, Andrew J., Vazquez, Francisca, Tsherniak, Aviad

“…Assays to study cancer cell responses to pharmacologic or genetic perturbations are typically restricted to using simple phenotypic readouts such as…”
Get full text

INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors by Li, Qing, Jiang, Baishan, Guo, Jiaye, Shao, Hong, Del Priore, Isabella S, Chang, Qing, Kudo, Rei, Li, Zhiqiang, Razavi, Pedram, Liu, Bo, Boghossian, Andrew S, Rees, Matthew G, Ronan, Melissa M, Roth, Jennifer A, Donovan, Katherine A, Palafox, Marta, Reis-Filho, Jorge S, de Stanchina, Elisa, Fischer, Eric S, Rosen, Neal, Serra, Violeta, Koff, Andrew, Chodera, John D, Gray, Nathanael S, Chandarlapaty, Sarat

“…Cyclin-dependent kinases 4 and 6 (CDK4/6) represent a major therapeutic vulnerability for breast cancer. The kinases are clinically targeted via ATP…”
Get more information

Group 3 medulloblastoma transcriptional networks collapse under domain specific EP300/CBP inhibition by Shendy, Noha A. M., Bikowitz, Melissa, Sigua, Logan H., Zhang, Yang, Mercier, Audrey, Khashana, Yousef, Nance, Stephanie, Liu, Qi, Delahunty, Ian M., Robinson, Sarah, Goel, Vanshita, Rees, Matthew G., Ronan, Melissa A., Wang, Tingjian, Kocak, Mustafa, Roth, Jennifer A., Wang, Yingzhe, Freeman, Burgess B., Orr, Brent A., Abraham, Brian J., Roussel, Martine F., Schonbrunn, Ernst, Qi, Jun, Durbin, Adam D.

“…Chemical discovery efforts commonly target individual protein domains. Many proteins, including the EP300/CBP histone acetyltransferases (HATs), contain…”
Get full text

Covalent disruptor of YAP-TEAD association suppresses defective Hippo signaling by Fan, Mengyang, Lu, Wenchao, Che, Jianwei, Kwiatkowski, Nicholas P, Gao, Yang, Seo, Hyuk-Soo, Ficarro, Scott B, Gokhale, Prafulla C, Liu, Yao, Geffken, Ezekiel A, Lakhani, Jimit, Song, Kijun, Kuljanin, Miljan, Ji, Wenzhi, Jiang, Jie, He, Zhixiang, Tse, Jason, Boghossian, Andrew S, Rees, Matthew G, Ronan, Melissa M, Roth, Jennifer A, Mancias, Joseph D, Marto, Jarrod A, Dhe-Paganon, Sirano, Zhang, Tinghu, Gray, Nathanael S

“…The transcription factor TEAD, together with its coactivator YAP/TAZ, is a key transcriptional modulator of the Hippo pathway. Activation of TEAD transcription…”
Get full text

Genetic dependencies associated with transcription factor activities in human cancer cell lines by Thatikonda, Venu, Supper, Verena, Wachter, Johannes, Kaya, Onur, Kombara, Anju, Bilgilier, Ceren, Ravichandran, Madhwesh C., Lipp, Jesse J., Sharma, Rahul, Badertscher, Lukas, Boghossian, Andrew S., Rees, Matthew G., Ronan, Melissa M., Roth, Jennifer A., Grosche, Sarah, Neumüller, Ralph A., Mair, Barbara, Mauri, Federico, Popa, Alexandra

“…Transcription factors (TFs) are important mediators of aberrant transcriptional programs in cancer cells. In this study, we focus on TF activity (TFa) as a…”
Get full text

Pan-cancer single-cell RNA-seq identifies recurring programs of cellular heterogeneity by Kinker, Gabriela S., Greenwald, Alissa C., Tal, Rotem, Orlova, Zhanna, Cuoco, Michael S., McFarland, James M., Warren, Allison, Rodman, Christopher, Roth, Jennifer A., Bender, Samantha A., Kumar, Bhavna, Rocco, James W., Fernandes, Pedro A. C. M., Mader, Christopher C., Keren-Shaul, Hadas, Plotnikov, Alexander, Barr, Haim, Tsherniak, Aviad, Rozenblatt-Rosen, Orit, Krizhanovsky, Valery, Puram, Sidharth V., Regev, Aviv, Tirosh, Itay

“…Cultured cell lines are the workhorse of cancer research, but the extent to which they recapitulate the heterogeneity observed among malignant cells in tumors…”
Get full text

Noncanonical open reading frames encode functional proteins essential for cancer cell survival by Prensner, John R., Enache, Oana M., Luria, Victor, Krug, Karsten, Clauser, Karl R., Dempster, Joshua M., Karger, Amir, Wang, Li, Stumbraite, Karolina, Wang, Vickie M., Botta, Ginevra, Lyons, Nicholas J., Goodale, Amy, Kalani, Zohra, Fritchman, Briana, Brown, Adam, Alan, Douglas, Green, Thomas, Yang, Xiaoping, Jaffe, Jacob D., Roth, Jennifer A., Piccioni, Federica, Kirschner, Marc W., Ji, Zhe, Root, David E., Golub, Todd R.

“…Although genomic analyses predict many noncanonical open reading frames (ORFs) in the human genome, it is unclear whether they encode biologically active…”
Get full text

Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling by Corsello, Steven M, Nagari, Rohith T, Spangler, Ryan D, Rossen, Jordan, Kocak, Mustafa, Bryan, Jordan G, Humeidi, Ranad, Peck, David, Wu, Xiaoyun, Tang, Andrew A, Wang, Vickie M, Bender, Samantha A, Lemire, Evan, Narayan, Rajiv, Montgomery, Philip, Ben-David, Uri, Garvie, Colin W, Chen, Yejia, Rees, Matthew G, Lyons, Nicholas J, McFarland, James M, Wong, Bang T, Wang, Li, Dumont, Nancy, O'Hearn, Patrick J, Stefan, Eric, Doench, John G, Harrington, Caitlin N, Greulich, Heidi, Meyerson, Matthew, Vazquez, Francisca, Subramanian, Aravind, Roth, Jennifer A, Bittker, Joshua A, Boehm, Jesse S, Mader, Christopher C, Tsherniak, Aviad, Golub, Todd R

“…Anti-cancer uses of non-oncology drugs have occasionally been found, but such discoveries have been serendipitous. We sought to create a public resource…”
Get full text

Genome-scale screens identify factors regulating tumor cell responses to natural killer cells by Sheffer, Michal, Lowry, Emily, Beelen, Nicky, Borah, Minasri, Amara, Suha Naffar-Abu, Mader, Chris C., Roth, Jennifer A., Tsherniak, Aviad, Freeman, Samuel S., Dashevsky, Olga, Gandolfi, Sara, Bender, Samantha, Bryan, Jordan G., Zhu, Cong, Wang, Li, Tariq, Ifrah, Kamath, Govinda M., Simoes, Ricardo De Matos, Dhimolea, Eugen, Yu, Channing, Hu, Yiguo, Dufva, Olli, Giannakis, Marios, Syrgkanis, Vasilis, Fraenkel, Ernest, Golub, Todd, Romee, Rizwan, Mustjoki, Satu, Culhane, Aedin C., Wieten, Lotte, Mitsiades, Constantine S.

“…To systematically define molecular features in human tumor cells that determine their degree of sensitivity to human allogeneic natural killer (NK) cells, we…”
Get full text

Discovering the anticancer potential of non-oncology drugs by systematic viability profiling by Corsello, Steven M., Nagari, Rohith T., Spangler, Ryan D., Rossen, Jordan, Kocak, Mustafa, Bryan, Jordan G., Humeidi, Ranad, Peck, David, Wu, Xiaoyun, Tang, Andrew A., Wang, Vickie M., Bender, Samantha A., Lemire, Evan, Narayan, Rajiv, Montgomery, Philip, Ben-David, Uri, Garvie, Colin W., Chen, Yejia, Rees, Matthew G., Lyons, Nicholas J., McFarland, James M., Wong, Bang T., Wang, Li, Dumont, Nancy, O’Hearn, Patrick J., Stefan, Eric, Doench, John G., Harrington, Caitlin N., Greulich, Heidi, Meyerson, Matthew, Vazquez, Francisca, Subramanian, Aravind, Roth, Jennifer A., Bittker, Joshua A., Boehm, Jesse S., Mader, Christopher C., Tsherniak, Aviad, Golub, Todd R.

Get full text

Targeting ROS production through inhibition of NADPH oxidases by Reis, Joana, Gorgulla, Christoph, Massari, Marta, Marchese, Sara, Valente, Sergio, Noce, Beatrice, Basile, Lorenzo, Törner, Ricarda, Cox, Huel, Viennet, Thibault, Yang, Moon Hee, Ronan, Melissa M., Rees, Matthew G., Roth, Jennifer A., Capasso, Lucia, Nebbioso, Angela, Altucci, Lucia, Mai, Antonello, Arthanari, Haribabu, Mattevi, Andrea

“…NADPH oxidases (NOXs) are transmembrane enzymes that are devoted to the production of reactive oxygen species (ROS). In cancers, dysregulation of NOX enzymes…”
Get full text

Systematic profiling of conditional pathway activation identifies context-dependent synthetic lethalities by Chang, Liang, Jung, Nancy Y., Atari, Adel, Rodriguez, Diego J., Kesar, Devishi, Song, Tian-Yu, Rees, Matthew G., Ronan, Melissa, Li, Ruitong, Ruiz, Paloma, Chaturantabut, Saireudee, Ito, Takahiro, van Tienen, Laurens M., Tseng, Yuen-Yi, Roth, Jennifer A., Sellers, William R.

“…The paradigm of cancer-targeted therapies has focused largely on inhibition of critical pathways in cancer. Conversely, conditional activation of signaling…”
Get full text

Translation of non-canonical open reading frames as a cancer cell survival mechanism in childhood medulloblastoma by Hofman, Damon A, Ruiz-Orera, Jorge, Yannuzzi, Ian, Murugesan, Rakesh, Brown, Adam, Clauser, Karl R, Condurat, Alexandra L, van Dinter, Jip T, Engels, Sem A G, Goodale, Amy, van der Lugt, Jasper, Abid, Tanaz, Wang, Li, Zhou, Kevin N, Vogelzang, Jayne, Ligon, Keith L, Phoenix, Timothy N, Roth, Jennifer A, Root, David E, Hubner, Norbert, Golub, Todd R, Bandopadhayay, Pratiti, van Heesch, Sebastiaan, Prensner, John R

“…A hallmark of high-risk childhood medulloblastoma is the dysregulation of RNA translation. Currently, it is unknown whether medulloblastoma dysregulates the…”
Get more information

Discovery and Characterization of Selective, First-in-Class Inhibitors of Citron Kinase by Maw, Joshua J., Coker, Jesse A., Arya, Tarun, Goins, Christopher M., Sonawane, Dhiraj, Han, Sang Hoon, Rees, Matthew G., Ronan, Melissa M., Roth, Jennifer A., Wang, Nancy S., Heemers, Hannelore V., Macdonald, Jonathan D., Stauffer, Shaun R.

“…Citron kinase (CITK) is an AGC-family serine/threonine kinase that regulates cytokinesis. Despite knockdown experiments implicating CITK as an anticancer…”
Get full text

Author Correction: Systematic profiling of conditional pathway activation identifies context-dependent synthetic lethalities by Chang, Liang, Jung, Nancy Y., Atari, Adel, Rodriguez, Diego J., Kesar, Devishi, Song, Tian-Yu, Rees, Matthew G., Ronan, Melissa, Li, Ruitong, Ruiz, Paloma, Chaturantabut, Saireudee, Ito, Takahiro, van Tienen, Laurens M., Tseng, Yuen-Yi, Roth, Jennifer A., Sellers, William R.

Get full text

Acute pharmacological degradation of ERK5 does not inhibit cellular immune response or proliferation by You, Inchul, Donovan, Katherine A, Krupnick, Noah M, Boghossian, Andrew S, Rees, Matthew G, Ronan, Melissa M, Roth, Jennifer A, Fischer, Eric S, Wang, Eric S, Gray, Nathanael S

“…Recent interest in the role that extracellular signal-regulated kinase 5 (ERK5) plays in various diseases, particularly cancer and inflammation, has grown…”
Get more information

Structure-Based Design of Y‑Shaped Covalent TEAD Inhibitors by Lu, Wenchao, Fan, Mengyang, Ji, Wenzhi, Tse, Jason, You, Inchul, Ficarro, Scott B., Tavares, Isidoro, Che, Jianwei, Kim, Audrey Y., Zhu, Xijun, Boghossian, Andrew, Rees, Matthew G., Ronan, Melissa M., Roth, Jennifer A., Hinshaw, Stephen M., Nabet, Behnam, Corsello, Steven M., Kwiatkowski, Nicholas, Marto, Jarrod A., Zhang, Tinghu, Gray, Nathanael S.

“…Transcriptional enhanced associate domain (TEAD) proteins together with their transcriptional coactivator yes-associated protein (YAP) and transcriptional…”
Get full text

Systematic identification of biomarker-driven drug combinations to overcome resistance by Rees, Matthew G., Brenan, Lisa, do Carmo, Mariana, Duggan, Patrick, Bajrami, Besnik, Arciprete, Michael, Boghossian, Andrew, Vaimberg, Emma, Ferrara, Steven J., Lewis, Timothy A., Rosenberg, Danny, Sangpo, Tenzin, Roth, Jennifer A., Kaushik, Virendar K., Piccioni, Federica, Doench, John G., Root, David E., Johannessen, Cory M.

“…The ability to understand and predict variable responses to therapeutic agents may improve outcomes in patients with cancer. We hypothesized that the basal…”
Get full text

Mechanism of Action of KL-50, a Candidate Imidazotetrazine for the Treatment of Drug-Resistant Brain Cancers by Huseman, Eric D., Lo, Anna, Fedorova, Olga, Elia, James L., Gueble, Susan E., Lin, Kingson, Sundaram, Ranjini K., Oh, Joonseok, Liu, Jinchan, Menges, Fabian, Rees, Matthew G., Ronan, Melissa M., Roth, Jennifer A., Batista, Victor S., Crawford, Jason M., Pyle, Anna M., Bindra, Ranjit S., Herzon, Seth B.

“…Aberrant DNA repair is a hallmark of cancer, and many tumors display reduced DNA repair capacities that sensitize them to genotoxins. Here, we demonstrate that…”
Get full text